Group 1 - The core product LZ901 is a recombinant vaccine developed by the company to prevent shingles and related complications in adults aged 40 and above [2] - The Phase I clinical trial of LZ901 in the United States was successfully completed in September 2025, demonstrating good safety and immunogenicity in both high-dose and low-dose groups compared to the placebo group [1] - The Phase I clinical trial began in February 2023, involving 66 healthy participants aged 50 to 70, and was designed as a randomized, double-blind, placebo-controlled, and dose-escalation study [1] Group 2 - The primary objective of the Phase I clinical trial was to verify the vaccine's safety, with only the low-dose group showing mild adverse reactions (4.35%), while no adverse reactions were reported in the high-dose and placebo groups [1] - LZ901 has achieved its clinical preset goals in the Phase III clinical trial in China and has received acceptance for its biological product license application from the National Medical Products Administration of China, which is currently under evaluation [2]
绿竹生物-B(02480.HK)于美国成功完成LZ901的I期临床试验